Journal
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
Volume 39, Issue 4, Pages 458-468Publisher
ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.clinre.2014.12.003
Keywords
-
Categories
Ask authors/readers for more resources
Background and objective: A systematic review was conducted to evaluate whether or not antiviral therapy with nucleotide/nucleoside analogs (NA) have survival benefit for patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative treatment. Methods: An electronic search of PubMed, EMBASE, and the Cochrane Library was performed to identify comparative studies in which the adjuvant effects of NA for patients with HBV-related HCC after curative treatment were evaluated. Primary outcome included survival rate, and secondary outcomes included tumor recurrence rate and side effects. Review Manager 5.1.6 software was used for meta-analysis. Results: Twelve studies involving 6682 patients were included in our review. Meta-analysis results demonstrated that significant differences favoring the antiviral treatment groups were observed in 1-year survival rate (RR: 0.65, 95% CI: 0.53-0.79, P < 0.0001), 3-year survival rate (RR: 0.58, 95% CI: 0.46-0.74, P < 0.0001), and 5-year survival rate (RR: 0.56, 95% CI: 0.43-0.74, P < 0.0001) compared with the control group. After NA was administered, recurrence was significantly reduced after one year (RR: 0.77, 95% CI: 0.64-0.93, P = 0.006) and three years (RR: 0.81, 95% CI: 0.71-0.93, P = 0.002) but not after five years (RR: 0.94, 95% CI: 0.76-1.16, P = 0.55) compared with non-NA therapy. Conclusion: Current evidence showed that antiviral therapy with NA could improve survival and reduce early recurrence for patients with HBV-related HCC after curative treatment. More high quality prospective trials are expected. (C) 2015 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available